General Information of Drug (ID: DMBYCU0)

Drug Name
Metyrosine Drug Info
Synonyms
Demser; Methyltyrosine; Metirosina; Metirosine; Metirosinum; Racemetirosina; Racemetirosine; Racemetirosinum; Metyrosine[USAN]; Racemetirosine [INN]; M 8131; MK 781; Alpha-MPT; Alpha-Methyltyrosine; Demser (TN); H 9/88; L 588357-0; L-AMPT; M-5185; MK-781; Metirosina [INN-Spanish]; Metirosine (INN); Metirosinum [INN-Latin]; Metyrosine (USP); Racemetirosina [INN-Spanish]; Racemetirosinum [INN-Latin]; DL-alpha-Methyltyrosine; L-588357-0; Alpha-Methyl-L-tyrosine; Alpha-Methyl-dl-tyrosine; Alpha-Methyl-p-tyrosine; Alpha-Methyl-para-tyrosine; A-methyl-L-p-tyrosine; Alpha-Methyl-L-P-Tyrosine; Alpha-Methyltyrosine, (L)-Isomer; DL-alpha-Methyl-p-tyrosine; L-alpha-Methyl-p-tyrosine; Alpha-Methyltyrosine, (D,L)-Isomer; DL-2-Methyl-3-(4-hydroxyphenyl)alanine; Alpha-Methyltyrosine, (+,-)-Isomer; L-2-Methyl-3-(4-hydroxy-phenyl)alanine; (+-)-alpha-Methyl-DL-tyrosine; (-)-(S)-2-Amino-3-(4-hydroxyphenyl)-2-methylpropionsaeure; (-)-alpha-Methyl-DL-tyrosine; (-)-alpha-Methyl-L-tyrosine; (2R)-2-amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid; (2S)-2-amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid; (R,S)-2-Amino-3-(4-hydroxyphenyl)-2-methylpropionsaeure; (S)-alpha-Methyltyrosine; 2-amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid; 4-Hydroxy-alpha-methylphenylalanine
Indication
Disease Entry ICD 11 Status REF
Pheochromocytoma 5A75 Approved [1]
Therapeutic Class
Anticancer Agents
Cross-matching ID
PubChem CID
441350
ChEBI ID
CHEBI:6912
CAS Number
CAS 672-87-7
TTD Drug ID
DMBYCU0
ACDINA Drug ID
D00427

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
L-Phenylalanine DMQXI9F Malnutrition 5B50-5B71 Approved [3]
L-Tyrosine DM9O8DT Malnutrition 5B50-5B71 Approved [4]
Tetrahydrobiopterin DMINZ4W Malnutrition 5B50-5B71 Approved [5]
L1-79 DMLHPVW Autism spectrum disorder 6A02 Phase 2 [6]
ProSavin DMJ42E6 Parkinson disease 8A00.0 Phase 1/2 [7]
OXB-102 DMXF9DM Parkinson disease 8A00.0 Phase 1/2 [8]
7,8-dihydrobiopterin DMQU4XM Discovery agent N.A. Investigative [9]
alpha-propyldopacetamide DMQKMX3 Discovery agent N.A. Investigative [10]
Meta-Tyrosine DM0748C Discovery agent N.A. Investigative [9]
3-iodotyrosine DMNZMH6 Discovery agent N.A. Investigative [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tyrosine 3-monooxygenase (TH) TTUHP71 TY3H_HUMAN Binder [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6956).
2 Dopamine beta-hydroxylase deficiency. A genetic disorder of cardiovascular regulation. Hypertension. 1991 Jul;18(1):1-8.
3 Selectivity and affinity determinants for ligand binding to the aromatic amino acid hydroxylases. Curr Med Chem. 2007;14(4):455-67.
4 Effect of metals and phenylalanine on the activity of human tryptophan hydroxylase-2: comparison with that on tyrosine hydroxylase activity. Neurosci Lett. 2006 Jul 3;401(3):261-5.
5 Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects. J Neural Transm Suppl. 2007;(72):113-20.
6 Effect of L1-79 on Core Symptoms of Autism Spectrum Disorder: A Case Series. Clin Ther. 2019 Oct;41(10):1972-1981.
7 Clinical pipeline report, company report or official report of Oxford BioMedica.
8 Clinical pipeline report, company report or official report of Oxford BioMedica.
9 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
10 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1243).